NCT04478266 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04478266
Title	SAR439859 Plus Palbociclib as First Line Therapy for Patients With ER(+) HER2(-) Advanced Breast Cancer (AMEERA-5)
Acronym	AMEERA-5
Recruitment	Terminated
Gender	both
Phase	Phase III
Variant Requirements	No
Sponsors	Sanofi
Indications	Her2-receptor negative breast cancer
Therapies	Letrozole + Palbociclib Amcenestrant + Goserelin + Palbociclib Goserelin + Letrozole + Palbociclib Amcenestrant + Palbociclib
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| POL \| NLD \| ITA \| HUN \| GBR \| FRA \| FIN \| ESP \| DEU \| CZE \| CAN \| BRA \| BGR \| BEL \| AUT \| AUS \| ARG

NCT04478266
Clinical Trial Detail